45 related articles for article (PubMed ID: 18716397)
1. Optimized combination therapy using bortezomib, TRAIL and TLR agonists in established breast tumors.
Lee S; Yagita H; Sayers TJ; Celis E
Cancer Immunol Immunother; 2010 Jul; 59(7):1073-81. PubMed ID: 20213120
[TBL] [Abstract][Full Text] [Related]
2. Studying Signaling Pathway Activation in TRAIL-Resistant Macrophage-Like Acute Myeloid Leukemia Cells.
Lomovskaya YV; Krasnov KS; Kobyakova MI; Kolotova AA; Ermakov AM; Senotov AS; Fadeeva IS; Fetisova EI; Lomovsky AI; Zvyagina AI; Akatov VS; Fadeev RS
Acta Naturae; 2024; 16(1):48-58. PubMed ID: 38698963
[TBL] [Abstract][Full Text] [Related]
3. Effectiveness of chemotherapy using bortezomib combined with homoharringtonine and cytarabine in refractory or relapsed acute myeloid leukemia: a phase II, multicenter, prospective clinical trial.
Zhang C; Gao D; Wang X; Sun X; Yan Y; Yang Y; Zhang J; Yan J
Front Oncol; 2023; 13():1142449. PubMed ID: 37664023
[TBL] [Abstract][Full Text] [Related]
4. Proteasome inhibition enhances the efficacy of volasertib-induced mitotic arrest in AML in vitro and prolongs survival in vivo.
Schnerch D; Schüler J; Follo M; Felthaus J; Wider D; Klingner K; Greil C; Duyster J; Engelhardt M; Wäsch R
Oncotarget; 2017 Mar; 8(13):21153-21166. PubMed ID: 28416751
[TBL] [Abstract][Full Text] [Related]
5. Phase II open-label study of recombinant circularly permuted TRAIL as a single-agent treatment for relapsed or refractory multiple myeloma.
Leng Y; Qiu L; Hou J; Zhao Y; Zhang X; Yang S; Xi H; Huang Z; Pan L; Chen W
Chin J Cancer; 2016 Sep; 35(1):86. PubMed ID: 27608772
[TBL] [Abstract][Full Text] [Related]
6. Trailing TRAIL Resistance: Novel Targets for TRAIL Sensitization in Cancer Cells.
Trivedi R; Mishra DP
Front Oncol; 2015; 5():69. PubMed ID: 25883904
[TBL] [Abstract][Full Text] [Related]
7. The impact of TNF superfamily molecules on overall survival in acute myeloid leukaemia: correlation with biological and clinical features.
Bolkun L; Lemancewicz D; Jablonska E; Szumowska A; Bolkun-Skornicka U; Ratajczak-Wrona W; Dzieciol J; Kloczko J
Ann Hematol; 2015 Jan; 94(1):35-43. PubMed ID: 25085377
[TBL] [Abstract][Full Text] [Related]
8. NF-κB pathways in hematological malignancies.
Gasparini C; Celeghini C; Monasta L; Zauli G
Cell Mol Life Sci; 2014 Jun; 71(11):2083-102. PubMed ID: 24419302
[TBL] [Abstract][Full Text] [Related]
9. Regulation of Tumor Necrosis Factor-related Apoptosis-inducing Ligand Expression in Primary Acute Leukemic Cells by Chemotherapeutics.
Chen S; Liu Y; Sun H; Sun L; Ma J; Wan D; Jiang Z; Zhang Q; Li T
Turk J Haematol; 2013 Sep; 30(3):263-8. PubMed ID: 24385805
[TBL] [Abstract][Full Text] [Related]
10. The Proteasome Inhibitor Bortezomib Sensitizes AML with Myelomonocytic Differentiation to TRAIL Mediated Apoptosis.
Dijk Mv; Murphy E; Morrell R; Knapper S; O'Dwyer M; Samali A; Szegezdi E
Cancers (Basel); 2011 Mar; 3(1):1329-50. PubMed ID: 24212664
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic effect of neural stem cells expressing TRAIL and bortezomib in mice with glioma xenografts.
Balyasnikova IV; Ferguson SD; Han Y; Liu F; Lesniak MS
Cancer Lett; 2011 Nov; 310(2):148-59. PubMed ID: 21802840
[TBL] [Abstract][Full Text] [Related]
12. Proteasome inhibition in myelodysplastic syndromes and acute myelogenous leukemia cell lines.
Liesveld JL; Rosell KE; Bechelli J; Lu C; Messina P; Mulford D; Ifthikharuddin JJ; Jordan CT; Phillips Ii GL
Cancer Invest; 2011 Aug; 29(7):439-50. PubMed ID: 21740082
[TBL] [Abstract][Full Text] [Related]
13. Assaying pharmacodynamic endpoints with targeted therapy: flavopiridol and 17AAG induced dephosphorylation of histone H1.5 in acute myeloid leukemia.
Wang L; Harshman SW; Liu S; Ren C; Xu H; Sallans L; Grever M; Byrd JC; Marcucci G; Freitas MA
Proteomics; 2010 Dec; 10(23):4281-92. PubMed ID: 21110323
[TBL] [Abstract][Full Text] [Related]
14. Bortezomib sensitizes human renal cell carcinomas to TRAIL apoptosis through increased activation of caspase-8 in the death-inducing signaling complex.
Brooks AD; Jacobsen KM; Li W; Shanker A; Sayers TJ
Mol Cancer Res; 2010 May; 8(5):729-38. PubMed ID: 20442297
[TBL] [Abstract][Full Text] [Related]
15. Proteasome inhibition and allogeneic hematopoietic stem cell transplantation: a review.
Koreth J; Alyea EP; Murphy WJ; Welniak LA
Biol Blood Marrow Transplant; 2009 Dec; 15(12):1502-12. PubMed ID: 19896073
[TBL] [Abstract][Full Text] [Related]
16. Antitumor activity of bortezomib alone and in combination with TRAIL in human acute myeloid leukemia.
Conticello C; Adamo L; Vicari L; Giuffrida R; Iannolo G; Anastasi G; Caruso L; Moschetti G; Cupri A; Palumbo GA; Gulisano M; De Maria R; Giustolisi R; Di Raimondo F
Acta Haematol; 2008; 120(1):19-30. PubMed ID: 18716397
[TBL] [Abstract][Full Text] [Related]
17. Bortezomib abolishes tumor necrosis factor-related apoptosis-inducing ligand resistance via a p21-dependent mechanism in human bladder and prostate cancer cells.
Lashinger LM; Zhu K; Williams SA; Shrader M; Dinney CP; McConkey DJ
Cancer Res; 2005 Jun; 65(11):4902-8. PubMed ID: 15930312
[TBL] [Abstract][Full Text] [Related]
18. Synergistic antiproliferative effect of arsenic trioxide combined with bortezomib in HL60 cell line and primary blasts from patients affected by myeloproliferative disorders.
Canestraro M; Galimberti S; Savli H; Palumbo GA; Tibullo D; Nagy B; Guerrini F; Piaggi S; Cine N; Metelli MR; Petrini M
Cancer Genet Cytogenet; 2010 Jun; 199(2):110-20. PubMed ID: 20471514
[TBL] [Abstract][Full Text] [Related]
19. Cooperation between Apo2L/TRAIL and bortezomib in multiple myeloma apoptosis.
Balsas P; López-Royuela N; Galán-Malo P; Anel A; Marzo I; Naval J
Biochem Pharmacol; 2009 Mar; 77(5):804-12. PubMed ID: 19100720
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
